MDxHealth SA ADR - Asset Resilience Ratio
MDxHealth SA ADR (MDXH) has an Asset Resilience Ratio of 0.09% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MDXH current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how MDxHealth SA ADR's Asset Resilience Ratio has changed over time. See shareholders equity of MDxHealth SA ADR for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MDxHealth SA ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MDxHealth SA ADR stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $110.00K | 0.09% |
| Total Liquid Assets | $110.00K | 0.09% |
Asset Resilience Insights
- Limited Liquidity: MDxHealth SA ADR maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MDxHealth SA ADR Industry Peers by Asset Resilience Ratio
Compare MDxHealth SA ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for MDxHealth SA ADR (2012–2023)
The table below shows the annual Asset Resilience Ratio data for MDxHealth SA ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.09% | $110.00K | $129.13 Million | +0.00pp |
| 2022-12-31 | 0.08% | $101.00K | $119.14 Million | -0.03pp |
| 2021-12-31 | 0.12% | $89.00K | $75.07 Million | -0.04pp |
| 2020-12-31 | 0.16% | $52.00K | $31.86 Million | +0.04pp |
| 2019-12-31 | 0.13% | $51.00K | $40.63 Million | +0.04pp |
| 2018-12-31 | 0.08% | $54.00K | $65.48 Million | +0.05pp |
| 2017-12-31 | 0.03% | $20.00K | $58.52 Million | -0.10pp |
| 2015-12-31 | 0.14% | $79.00K | $57.74 Million | 0.00pp |
| 2014-12-31 | 0.14% | $43.00K | $30.95 Million | -0.01pp |
| 2013-12-31 | 0.15% | $44.00K | $29.38 Million | +0.06pp |
| 2012-12-31 | 0.08% | $17.00K | $20.00 Million | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more